Results for the Third Quarter and YTD September 2025

Medistim delivers another strong quarter, with solid growth and record sales year-to-date. Sales revenues grew 25.7% in Q3 to MNOK 166.8 (MNOK 132.8). Year-to-date, revenues reached a record MNOK 517.5, up 25.8% from last year (MNOK 411.5). Currency-neutral sales of own products increased 29.8% for the quarter and 28.0% year-to-date.Strong regional performance:

🔹 AMERICAS up 35.7%

🔹 APAC up 194%

🔹 EMEA down 11.8%, yet up 1% year to date

🔹 Scandinavia distributor sales up 4.4% for the quarter and 16.2% year to date

Operating profit (EBIT) grew 27.1% to MNOK 40.6 with a 24.3% margin (MNOK 31.9, 24.0%) for the quarter.Year-to-date, EBIT reached a record of MNOK 153.9, up 46.2% with a 29.7% margin.

Read the full Q3 2025 report and presentation here: https://lnkd.in/dktfBxgX